Apparent Cooperativity in Multivalent Verotoxin-Globotriosyl Ceramide Binding: Kinetic and Saturation Binding Studies with [¹²⁵I]-Verotoxin. M.G. Peter and C.A. Lingwood. Biochim. Biophys. Acta (Molecular Basis of Disease) (2000) 1501(2-3):116-124.

Alpha-Galactose Based Neoglycopeptides. Inhibition of Verotoxin Binding. P. Arya, K.M. Kutterer, H. Qin, J. Roby, M.L. Barnes, S. Lin, C.A. Lingwood and M.G. Peter. Bioorg. Med. Chem. (1999) 7(12):2823-33.

The endothelin system in the (mRen2)27 transgenic rat model of hypertension and cardiac hypertrophy. M.G. Peter, J.C-M. YU, H. Marquardt and M. Paul. 9th International Symposium on SHR and Cardiovascular Genetics. Montreal, Quebec, Canada: November 13-16, 1997.

Characterisation of Endothelin Receptor Selective Agonist BQ3020 and Antagonists BQ123, FR139317, BQ788, 50235, Ro462005 and Bosentan in the Heart. M.G. Peter and A.P. Davenport. Br. J. Pharmacol. (1996) 117:455-462.

Selectivity of [¹²⁵I]-PD151242 for Human, Rat and Porcine Endothelin ET_A Receptors in the Heart. M.G. Peter and A.P. Davenport. Br. J. Pharmacol. (1995) 114:297-302.

Delineation of Endothelin Receptors in Human Left Ventricular Smooth Muscle Cells. M.G. Peter and A.P. Davenport. J. Cardiovasc. Pharmacol. (1995) 26(Suppl. 3):S355-S357.

A novel non-peptide, myricerone caffeoyl ester (50235) is selective for human cardiovascular ET_A receptors and inhibits endothelin-1 responses in isolated blood vessels. J.J. Maguire, C.R. Bacon, M.G. Peter, M. Fujimoto and A.P. Davenport. Br. J. Pharmacol. (1994) 112:161.

Upregulation of the endothelin ET_A receptors in left ventricle from failing human hearts demonstrated using competition binding studies with FR139317. M.G. Peter and A.P. Davenport. Br. J. Pharmacol. (1996) 117:270.